Clinical Trial: PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: PET-MRI: Evaluation, Optimization and Clinical Implementation

Brief Summary: This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac diseases, or neurologic diseases. PET-MRI combines two imaging methods that can be used to evaluate disease. PET-MRI is similar to standard-of-care PET-CT, but exposes the patient to less radiation. It is not yet known whether PET-MRI produces better image quality than PET-CT in diagnosing patients with cancer, cardiac disease, or neurologic disease.

Detailed Summary:

PRIMARY OBJECTIVES:

I. To assess and optimize image quality of PET and MRI focusing on technical artifacts and their correction.

II. To assess the accuracy of PET quantification based on MR attenuation correction (MRAC) derived from various MRI sequences and reconstruction algorithms including the effect of routinely used Gadolinium-based contrast agents on MRAC.

III. To determine the clinical and diagnostic accuracy of PET-MRI in comparison to standard-of-care diagnostic imaging.

IV. To assess the efficacy and workflow in combining PET and MRI in one single examination as compared to separate imaging studies.

V. To assess the potential for radiation dose reduction if PET-CT is substituted by PET-MRI, thus avoiding the radiation exposure from the CT-component.


Sponsor: Case Comprehensive Cancer Center

Current Primary Outcome:

  • Overall image quality scores [ Time Frame: Day 1 ]
    Overall image quality scores obtained from the two imaging modalities will be compared with the hypothesis that hybrid PET-MRI images is as good as PET-CT images or superior (not inferior) to the PET-CT images. Evaluation of overall image quality will be assessed using the following criteria: 1=excellent, 2=good, 3=acceptable, 4=poor, 5=not acceptable. A Wilcoxon (Mann-Whitney) rank-sum test with a 0.100 significance level will be used.
  • Lesion based standard uptake values (SUV) [ Time Frame: Day 1 ]
    Lesion based SUV will be estimated and compared for PET-MR and PET-CT images in normal organs and compared. A two-sided two-sample t-test will be used to show significance of difference.
  • Area under the receiver operating characteristic curve [ Time Frame: Day 1 ]
    A two-sided z-test will be used to detect the difference in the area under the curve showing the sensitivity, specificity, positive and negative predictive values as well as accuracy of diagnostic information.
  • Time effort associated with the PET-MRI versus PET-CT with MRI [ Time Frame: Day 1 ]
    Statistical difference in time between PET-MRI versus sequential approach for PET-CT plus MRI. Workflow with shortest timely efforts and sufficient diagnostic information will be established as routine procedure.
  • Radiation dose reduction with PET-MRI [ Time Frame: Day 1 ]
    Dose measurements will be used to calculate effective radi

    Original Primary Outcome: Same as current

    Current Secondary Outcome:

    Original Secondary Outcome:

    Information By: Case Comprehensive Cancer Center

    Dates:
    Date Received: March 7, 2014
    Date Started: March 7, 2013
    Date Completion: September 2017
    Last Updated: April 24, 2017
    Last Verified: April 2017